Fig. 2
From: Analysis of in vivo turnover of tau in a mouse model of tauopathy
Turnover of soluble tau in pro-aggregant mice and anti-aggregant mice. a Doxycycline specifically reduced human tau in intracellular fractions of pro-aggregant mice. Human (black bars) and murine tau levels (white bars) in intracellular soluble fractions following doxycycline treatment were measured (n = 4 for day 10, n = 5 for day 4 and day 18, n = 7 for day 8, n = 12 for day 0. ****p < 0.0001) in pro-aggregant mice. b Doxycycline specifically reduced human tau in ISF of pro-aggregant mice. The levels of human tau (black bars) and lactate (white bars) in ISF of pro-aggregant following doxycycline treatment were measured (n = 6 for day 0, n = 5 for day 3, n = 4 for day 7, n = 4 for day 9, n = 5 for day 17, n = 4-6/group). c Semi-log plot of intracellular (black circles) and extracellular soluble human tau (white circles) changes (Log % soluble human tau) over time in pro-aggregant mice d Phosphorylated tau showed different clearance kinetics in brain of pro-aggregant mice. Semi-log plot of soluble human tau (white circles, Log % soluble human tau), and phosphorylated soluble tau (black circles, Log % soluble human pS202/pT205, gray squares, Log % soluble pT231/pS235 tau, white squares, Log % soluble murine and human pS202/pT205, white triangles, Log % soluble human pS396) over time in pro-aggregant mice. e Phosphorylated tau showed different clearance kinetics in the brain of anti-aggregant mice. Semi-log plot of soluble human tau (white circles, Log % soluble human tau), and phosphorylated soluble tau (black circles, Log % soluble human pS202/pT205, gray triangles, Log % phosphorylated murine and human tau pS202/pT205, white squares, Log % soluble human pS396) over time in anti-aggregant mice